FOR IMMEDIATE RELEASE
Wednesday, October 29, 2003
CONTACT:
Floyd E. Bloom, M.D.
Founding Chief Executive Officer
(858) 677-0466
NEUROME Announces Discovery Research
Collaboration with WYETH
LA JOLLA, CA, October 29, 2003 - Neurome, Inc., a privately
held biotech company focused on molecular and cellular neuropathology,
announced today that it has entered into a research agreement
with Wyeth (NYSE:WYE), in which Neurome will employ its proprietary
technologies and expertise in quantitative neuropathology
to assist Wyeth in its Discovery Research efforts involving
treatment of Central Nervous System (CNS) disorders. Under
the terms of the multi-year agreement, Neurome will receive
research funding from Wyeth.
In this collaboration, Neurome and Wyeth will work together
to investigate a number of aspects of CNS disease, beginning
with the comprehensive evaluation and morphological analysis
of one of Wyeth’s transgenic animal models of Alzheimer’s
disease used to evaluate selected preclinical compounds. The
collaboration will leverage Neurome’s extensive experience
with animal models of CNS diseases and proprietary technologies
(the Neurome Technologies) to derive quantitative 3-D information,
including volumetric analysis, on these animals.
“We are delighted that Wyeth has chosen to work with
Neurome." said Floyd E. Bloom, M.D., Founding Chief Executive
Officer and Chairman of the Board of Neurome and Chairman
of the Department of Neuropharmacology at The Scripps Research
Institute. “The Neurome Technologies and tools created
at Neurome were designed to provide accelerated and highly
focused goal-directed methods for drug development and research.
We look forward to a productive relationship that will accelerate
Wyeth’s Research’s efforts in Neuroscience.”
About Neurome
Neurome, Inc. performs contract brain research for pharmaceutical
and biotechnology companies while at the same time pursuing
its own in-house and collaborative research protocols. The
data collected from these efforts will populate an evolving,
comprehensive database available by subscription and useful
on a broad level for analyses of mouse models of brain function
and disease. Neurome develops standardized, quantitative databases
that accurately depict and integrate gene expression patterns
in the three-dimensional context of the brain’s structures,
circuits, and cells, and deploys these databases in primary
research directed toward the discovery and development of
gene targets for enhancement of brain function and treatment
of brain-based disease. In this regard, the application of
the Neurome Technologies will provide rigorous, quantitative
data that are optimally suited to the measurement of subtle
cell-type specific shifts in gene expression, as well as progression
and prevention of degenerative events affecting specific cell
classes and brain regions. For more information, please visit
Neurome’s website at www.neurome.com.
Except for historical statements, this press release contains
forward-looking statements involving significant risks and
uncertainties, and a number of factors, both foreseen and
unforeseen, could cause actual results to differ materially
from Neurome's current expectations. Forward-looking statements
include those which express a plan, belief, expectation, estimation,
anticipation, intent, contingency, future development or similar
expression. Readers are cautioned that forward-looking statements
are not guarantees of future performance and that undue reliance
should not be placed on such statements. Forward-looking statements
speak only as of the dates on which they were made. Neurome
undertakes no obligation to publicly update or revise any
forward-looking statements or to make any other forward-looking
statements, whether as a result of new information, future
events or otherwise unless required to do so by the securities
laws.
|
